Atypical  ||| S:0 E:9 ||| JJ
subtrochanteric  ||| S:9 E:25 ||| JJ
fractures  ||| S:25 E:35 ||| NN
after  ||| S:35 E:41 ||| IN
long-term  ||| S:41 E:51 ||| JJ
bisphosphonate  ||| S:51 E:66 ||| JJ
therapy  ||| S:66 E:74 ||| NN
There  ||| S:74 E:80 ||| EX
have  ||| S:80 E:85 ||| VBP
been  ||| S:85 E:90 ||| VBN
many  ||| S:90 E:95 ||| JJ
reports  ||| S:95 E:103 ||| NNS
published  ||| S:103 E:113 ||| VBN
in  ||| S:113 E:116 ||| IN
recent  ||| S:116 E:123 ||| JJ
years  ||| S:123 E:129 ||| NNS
on  ||| S:129 E:132 ||| IN
atypical  ||| S:132 E:141 ||| JJ
subtrochanteric  ||| S:141 E:157 ||| JJ
fractures  ||| S:157 E:167 ||| NN
after  ||| S:167 E:173 ||| IN
long-term  ||| S:173 E:183 ||| JJ
bisphosphonates  ||| S:183 E:199 ||| JJ
therapy ||| S:199 E:206 ||| NN
.  ||| S:206 E:208 ||| .
In  ||| S:208 E:211 ||| IN
a  ||| S:211 E:213 ||| DT
description  ||| S:213 E:225 ||| NN
of  ||| S:225 E:228 ||| IN
a  ||| S:228 E:230 ||| DT
few  ||| S:230 E:234 ||| JJ
series  ||| S:234 E:241 ||| NN
of  ||| S:241 E:244 ||| IN
cases ||| S:244 E:249 ||| NNS
,  ||| S:249 E:251 ||| ,
fractures  ||| S:251 E:261 ||| VBG
of  ||| S:261 E:264 ||| IN
typical  ||| S:264 E:272 ||| JJ
clinical  ||| S:272 E:281 ||| JJ
course  ||| S:281 E:288 ||| NN
and  ||| S:288 E:292 ||| CC
radiological  ||| S:292 E:305 ||| JJ
image  ||| S:305 E:311 ||| NN
have  ||| S:311 E:316 ||| VBP
been  ||| S:316 E:321 ||| VBN
documented ||| S:321 E:331 ||| VBN
.  ||| S:331 E:333 ||| .
These  ||| S:333 E:339 ||| DT
fractures  ||| S:339 E:349 ||| NNS
are  ||| S:349 E:353 ||| VBP
estimated  ||| S:353 E:363 ||| VBN
as  ||| S:363 E:366 ||| IN
very  ||| S:366 E:371 ||| RB
rare  ||| S:371 E:376 ||| JJ
( ||| S:376 E:377 ||| -LRB-
2.3  ||| S:377 E:381 ||| CD
per  ||| S:381 E:385 ||| IN
10,000  ||| S:385 E:392 ||| CD
patient-years ||| S:392 E:405 ||| NN
) ||| S:405 E:406 ||| -RRB-
.  ||| S:406 E:408 ||| .
It  ||| S:408 E:411 ||| PRP
is  ||| S:411 E:414 ||| VBZ
suggested  ||| S:414 E:424 ||| VBN
that  ||| S:424 E:429 ||| IN
a  ||| S:429 E:431 ||| DT
subsequent  ||| S:431 E:442 ||| JJ
use  ||| S:442 E:446 ||| NN
of  ||| S:446 E:449 ||| IN
steroids  ||| S:449 E:458 ||| NNS
or  ||| S:458 E:461 ||| CC
proton  ||| S:461 E:468 ||| NNS
pump  ||| S:468 E:473 ||| VBP
inhibitors  ||| S:473 E:484 ||| VBN
with  ||| S:484 E:489 ||| IN
bisphosphonates  ||| S:489 E:505 ||| NNS
may  ||| S:505 E:509 ||| MD
increase  ||| S:509 E:518 ||| VB
the  ||| S:518 E:522 ||| DT
risk  ||| S:522 E:527 ||| NN
of  ||| S:527 E:530 ||| IN
fracture  ||| S:530 E:539 ||| JJ
occurrence ||| S:539 E:549 ||| NN
.  ||| S:549 E:551 ||| .
